Výsledky vyhledávání - "Mattias Levin"

Akademický článek

RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties

Autor: Barnabas Nyesiga, Mattias Levin, Anna Säll, Anna Rosén, Kim Jansson, Sara Fritzell, Karin Hägerbrand, Dietmar Weilguny, Laura von Schantz

Publikováno v: mAbs, Vol 16, Iss 1 (2024)

ABSTRACTDespite the large number of existing bispecific antibody (bsAb) formats, the generation of novel bsAbs is still associated with development and bioprocessing challenges. Here, we present RUBY, a novel bispecific antibody format that allows ra

Externí odkaz: https://doaj.org/article/3554ed116f6c45079b118217d1d8fd6f

Zobrazit plný text záznamu

Akademický článek

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)

Background Indications with poor T-cell infiltration or deficiencies in T-cell priming and associated unresponsiveness to established immunotherapies represent an unmet medical need in oncology. CD40-targeting therapies designed to enhance antigen pr

Externí odkaz: https://doaj.org/article/3ded16f9cf504c5983b33e362b58d5fd

Zobrazit plný text záznamu

Abstract 2939: ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo

Autor: Karin Hägerbrand, Anette Sundstedt, Mattias Levin, Yago Pico de Coaña, Laura Varas, Lill Ljung, Anneli Nilsson, Mona Celander, David Gomez Jimenez, Hampus Andersson, Malin Lindstedt, Peter Ellmark

Publikováno v: Cancer Research. 83:2939-2939

Alligator’s Neo-X-Prime platform aims to enable antigen presenting cells to efficiently enhance priming of tumor neoantigen-specific T cells. We have demonstrated that binding of a CD40 x TAA bispecific antibody (bsAb) to CD40 on dendritic cells (D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a0c7af65c545d4bfc779505d1da165c0
https://doi.org/10.1158/1538-7445.am2023-2939

Zobrazit plný text záznamu

751 Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb

Autor: Barnabas Nyesiga, Mia Thagesson, Anna Rosén, Karin Hägerbrand, Mattias Levin, Karin Barchan, Laura Varas, Anette Sundstedt, Anna Säll, Doreen Werchau, Peter Ellmark, Lill Ljung, Laura Von Schantz, Eva Lindqvist, Adnan Deronic

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

BackgroundAlligator's Neo-X-Prime platform aims to enable antigen presenting cells to efficiently enhance priming of tumor neoantigen-specific T cells with the goal of overcoming PD-1 resistance in certain tumor types. We hypothesize that binding of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::254b3a98cca7dddc470b999478d652d6
https://doaj.org/article/9e6a3658910c424b887736939f0b115c

Zobrazit plný text záznamu

Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy

Autor: Maria, Mikus, Arash, Zandian, Ronald, Sjöberg, Carl, Hamsten, Björn, Forsström, Morgan, Andersson, Lennart, Greiff, Mathias, Uhlén, Mattias, Levin, Peter, Nilsson, Marianne, van Hage, Mats, Ohlin

Publikováno v: The Journal of allergy and clinical immunology. 147(3)

The interaction of allergens and allergen-specific IgE initiates the allergic cascade after crosslinking of receptors on effector cells. Antibodies of other isotypes may modulate such a reaction. Receptor crosslinking requires binding of antibodies t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::672504a4c0a69070c6499273087bdc1a
https://pubmed.ncbi.nlm.nih.gov/32791163

Zobrazit plný text záznamu

Persistence and evolution of allergen-specific IgE repertoires during subcutaneous specific immunotherapy

Autor: Adriano Mari, Katherine J. L. Jackson, Lennart Greiff, Jasmine J. King, Timothy J. Looney, Jacob Glanville, Mattias Levin, Scott D. Boyd, Andrew Fire, Ramona A. Hoh, Morgan Andersson, Mats Ohlin

Publikováno v: Journal of Allergy and Clinical Immunology. 137(5):1535-1544

Background Specific immunotherapy (SIT) is the only treatment with proved long-term curative potential in patients with allergic disease. Allergen-specific IgE is the causative agent of allergic disease, and antibodies contribute to SIT, but the effe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9971855de1fc97a9116ce791449c009

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání